Nirsevimab Effective for Protecting Infants From RSV Lower Respiratory Tract Disease
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 30, 2025 -- Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according to a study published online July 22 in Pediatrics.
Amber Hsiao, Ph.D., M.P.H., from the Kaiser Permanente Vaccine Study Center in Oakland, California, and colleagues examined nirsevimab effectiveness against polymerase chain reaction (PCR)-confirmed RSV LRTD and RSV-associated health care utilization during the 2023 to 2024 RSV season at Kaiser Permanente Northern California.
The study included 31,900 infants, 49.1 percent of whom received nirsevimab. The researchers identified 35 and 462 RSV LRTD episodes among nirsevimab-immunized infants and nonimmunized infants (6.10 and 58.51/1,000 person-years, respectively). Nirsevimab effectiveness was 87.2, 98.0, and 71.0 percent against RSV LRTD, hospitalized RSV LRTD, and PCR-confirmed RSV, respectively. Fewer encounters (adjusted means difference, −0.86) and lower odds of hospitalization (odds ratio, 0.11) were seen for nirsevimab-immunized infants with RSV LRTD than nonimmunized infants.
"These findings support the Advisory Committee on Immunization Practice's recommendation for eligible infants aged <8 months entering their first RSV season to receive nirsevimab to reduce the risk of RSV infection," the authors write.
The study was funded by Sanofi, the manufacturer of nirsevimab.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Seniors With RSV-Linked Hospitalization Have Increased Cardiovascular Outcomes
THURSDAY, July 24, 2025 -- In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events...
35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
TUESDAY, July 22, 2025 -- Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV)...
Odds of Cardiovascular Events Up for RSV Hospitalization Versus COVID-19 Hospitalization
WEDNESDAY, May 28, 2025 -- Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event compared with COVID-19...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.